osimertinib trial summary

All type of patients: 2 trials - AURA 3 - FLAURA

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	0.63 [0.45 0.88]	p=0.04	0	556	1	FLAURA,
death (overall survival)	no data
progression or death (progression free survival PFS)	0.45 [0.36 0.56]	p=0.04	0	556	1	FLAURA,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	0.30 [0.22 0.40]	p=0.04	0	-18	1	AURA 3,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

First line: 1 trials - FLAURA

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	0.63 [0.45 0.88]	p=0.04	0	556	1	FLAURA,
death (overall survival)	no data
progression or death (progression free survival PFS)	0.45 [0.36 0.56]	p=0.04	0	556	1	FLAURA,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Second line: 1 trials - AURA 3

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	0.30 [0.22 0.40]	p=0.04	0	-18	1	AURA 3,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Osimertinib EGFR inhibitors